ArticleAIDS (London, England)2016
Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study.
Article in AIDS (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
Adolescent Master Protocol
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis.The Lancet. Child & adolescent health · 2022Pooled it
- Pediatric Neurodevelopmental Functioning After In Utero Exposure to Triple-NRTI vs. Dual-NRTI + PI ART in a Randomized Trial, Botswana.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Hearing Measures in Children Perinatally HIV-exposed and Uninfected in the PHACS SMARTT Study.The Pediatric infectious disease journal · 2026Article
- Maternal Use of Integrase Strand Transfer Inhibitors During Pregnancy and Infant Neurodevelopment.JAMA network open · 2025Article
- Brief Report: Prenatal Antiretroviral Exposure and Concomitant Neurodevelopmental Problems Among 5-Year-Old Children Who Are HIV-Exposed and Uninfected.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Birth outcomes following bictegravir exposure during pregnancy.AIDS (London, England) · 2025Article
- CEST MRI detects antiretroviral drug toxicities in the developing mouse brain.Frontiers in pharmacology · 2025Article
- Perinatal exposure to atazanavir-based antiretroviral regimens in a mouse model leads to differential long-term motor and cognitive deficits dependent on the NRTI backbone.Frontiers in molecular neuroscience · 2024Article
- Neurodevelopment among children exposed to HIV and uninfected in sub-Saharan Africa.Journal of the International AIDS Society · 2023Article
- Neurodevelopment of children who are HIV-exposed and uninfected in Kenya.Journal of the International AIDS Society · 2023Article
- Antiretroviral Options and Treatment Decisions During Pregnancy.Paediatric drugs · 2023Review
- In Utero Antiretroviral Exposure and Risk of Neurodevelopmental Problems in HIV-Exposed Uninfected 5-Year-Old Children.AIDS patient care and STDs · 2023Article
- Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data.Cells · 2021Review
- The University of Zimbabwe College of Health Sciences (UZ-CHS) BIRTH COHORT study: rationale, design and methods.BMC infectious diseases · 2020Article
- In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.PloS one · 2020Article
- Growth and Neurodevelopment of HIV-Exposed Uninfected Children: a Conceptual Framework.Current HIV/AIDS reports · 2019Review
- Contemporary Issues in Pregnancy (and Offspring) in the Current HIV Era.Current HIV/AIDS reports · 2019Review
- Maternal Factors Associated With Infant Neurodevelopment in HIV-Exposed Uninfected Infants.Open forum infectious diseases · 2019Article
- A hierarchical modeling approach for assessing the safety of exposure to complex antiretroviral drug regimens during pregnancy.Statistical methods in medical research · 2019Article
- Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies.AIDS (London, England) · 2018Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveTo evaluate the safety of in-utero exposure to atazanavir and neurodevelopment in perinatally HIV-exposed but uninfected (PHEU) infants.
designProspective cohort study of mother-PHEU infant pairs in the Surveillance Monitoring for ART Toxicities protocol of the Pediatric HIV/AIDS Cohort Study.
methodsPregnant women living with HIV who initiated an antiretroviral regimen during pregnancy were followed from the date of antiretroviral initiation. Women were classified according to whether the antiretroviral regimen contained atazanavir and the trimester of antiretroviral initiation. Neurodevelopment at 9-15 months was evaluated using the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III). We estimated mean differences for the five Bayley-III domains for atazanavir-containing regimens versus all other regimens. Models included baseline covariates and adjustment for failure to complete the Bayley-III using inverse probability weighting.
resultsPHEU infants were exposed in utero to atazanavir-containing (n = 167) and nonatazanavir-containing (n = 750) antiretroviral regimens. The adjusted mean differences (95% confidence interval) in Bayley-III domain scores for initiating an atazanavir-containing regimen in the first trimester were: cognitive, -1.5 (-6.2, 3.2); language, -3.3 (-7.6, 1.0); motor, -2.9 (-7.7, 1.9); social-emotional, 0.1 (-6.2, 6.4); and adaptive behavior, -0.1 (-4.3, 4.0). The mean differences for the second or third trimester were: cognitive, 0.4 (-3.2, 4.0); language, -3.4 (-6.2, -0.5); motor, 0.3 (-2.9, 3.4); social-emotional, -5.9 (-9.4, -2.3); and adaptive behavior, -2.5 (-5.9, 0.8).
conclusionIn-utero exposure to atazanavir-containing regimens compared with non-atazanavir-containing regimens may adversely affect language and social-emotional development in PHEU infants during the first year of life, but the absolute difference is small.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.